Transgenic News and Research

RSS

Study: Bone marrow transplantation may prolong period of cancer-free survival

Bone marrow transplantation with genetically modified cells may prolong the period of cancer-free survival, suggests a study led by Dr. Vivek Rangnekar, associate director of translational research for the Markey Cancer Center at the University of Kentucky.

25 Aug 2011

Green tea shows promise against two types of tumors, HHS

A compound found in green tea shows great promise for the development of drugs to treat two types of tumors and a deadly congenital disease. The discovery is the result of research led by Principal Investigator, Dr. Thomas Smith at The Donald Danforth Plant Science Center and his colleagues at The Children's Hospital of Philadelphia.

16 Aug 2011

Caffeine in sunscreens may protect from skin cancer: Study

Studies have revealed that drinking caffeinated beverages reduces one’s chances of developing some types of cancer, including UV-associated skin cancer. Now, researchers propose a possible mechanism for this observation—the inhibition of a DNA repair pathway that sensitizes cells to death after sun exposure.

15 Aug 2011

Medical College of Wisconsin to establish National Center for Systems Biology

The Medical College of Wisconsin has received a five-year, $13 million grant to establish a National Center for Systems Biology.

12 Aug 2011

New approach reduces cyanogen, enhances nutritional value in root crop

Researchers working at The Donald Danforth Plant Science Center have made an another advancement in their efforts to improve the root crop cassava which is a major source of calories to 700 million people worldwide, primarily living in the developing world.

3 Aug 2011

Insect virus holds key to safer stem cell therapy: Singapore scientists

The future of regenerative medicine lies in harnessing the potential of the human body to renew and repair itself. Now, scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a new genetic engineering technique that promises safer stem cell therapy for cancer patients. Using an insect virus, the team of researchers successfully inserted a therapeutic gene into a safe site in the DNA of human embryonic stem cells without compromising the functionality of the engineered cells.

28 Jul 2011

UK regulators approve Europe's first clinical trial of plant-derived antibody for HIV

UK regulators have approved Europe's first clinical trial of a monoclonal antibody produced from genetically modified plants. This landmark decision sets the stage for the testing, in humans, of an anti-HIV product made from genetically modified tobacco plants. It will open the door for trials of additional plant-derived medicines treating a range of diseases.

22 Jul 2011

Experts present new research at 2011 Alzheimer's Association ICAD

Experts from the Center of Excellence on Brain Aging at NYU Langone Medical Center will present new research at the 2011 Alzheimer's Association International Conference on Alzheimer's disease to be held in Paris, France from July 16 - 21.

21 Jul 2011

Clinical study of anti-HIV antibody made from genetically modified tobacco plants

Pharmaceuticals can be produced by plants. Antibodies that have been produced in tobacco plants will now for the first time be tested in a clinical study.

21 Jul 2011

Beta HPV prophylactic strategies may have a positive impact on prevention of NMSC

Non-melanoma skin cancer is the most common form of malignancy in adult Caucasian populations, with more than a million cases recorded each year in the USA alone.

21 Jul 2011

New transgenic mouse could predict toxicity of targeted cancer drugs

Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug.

20 Jul 2011

Sigma introduces CompoZr Targeted Integration Kit – mRosa26

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich Corporation today announced the launch of CompoZr Targeted Integration Kit – mRosa26, which can precisely and rapidly integrate transgenes into the mouse genome at the Rosa26 safe harbor locus.

19 Jul 2011

genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

genOway and bluebird bio report today genOway acquisition of an exclusive worldwide license for the RMCE technology (developed at the Massachusetts Institute of Technology) in the field of genetically modified rodents.

12 Jul 2011

Genetically engineered pigs may help overcome donor organ shortage

A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.

1 Jul 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

Redefinition of cardiac hypertrophy term needed

The European Society of Cardiology (ESC) Working Group on Myocardial Function is calling for a redefinition of the term cardiac hypertrophy which is currently used to describe changes to the morphology (structure) of the heart. Instead the position paper, published online today in the European Journal of Heart Failure, suggests that use of the general term myocardial remodelling should be preferred.

27 Jun 2011

Lilly, Harbour Antibodies complete non-exclusive research and licence deal

Harbour Antibodies BV, an Erasmus MC spin-off company, announced today the completion of a non-exclusive research and licence agreement with Eli Lilly and Company, a global pharmaceutical company, to generate and develop human therapeutic antibodies comprising immunoglobulin heavy and light chains(H2L2) using one of Harbour's transgenic mouse antibody discovery platforms.

27 Jun 2011

Maize-derived collagen has proline hydroxylation levels similar to human collagen

Synthetic collagen has a wide range of applications in reconstructive and cosmetic surgery and in the food industry. For proper function in animals a certain number of prolines within the protein need to be hydroxylated. BioMed Central's open access journal BMC Biotechnology reports that for the first time the α1 chain of type 1 collagen has been produced in maize with similar levels of proline hydroxylation to human collagen.

24 Jun 2011

Scientists uncover novel mechanism linked to Spinocerebellar ataxia 7

A team of scientists, led by researchers at the University of California, San Diego School of Medicine, have uncovered a novel mechanism regulating gene expression and transcription linked to Spinocerebellar ataxia 7, an inherited neurological disorder.

22 Jun 2011